Clear Harbor Asset Management LLC Purchases New Holdings in AnaptysBio, Inc. $ANAB

Clear Harbor Asset Management LLC purchased a new position in shares of AnaptysBio, Inc. (NASDAQ:ANAB) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 11,550 shares of the biotechnology company’s stock, valued at approximately $780,000.

Several other hedge funds and other institutional investors have also bought and sold shares of ANAB. E Fund Management Co. Ltd. bought a new position in AnaptysBio in the 2nd quarter valued at $208,000. Latash Investments LLC bought a new stake in shares of AnaptysBio during the 2nd quarter worth $297,000. DCF Advisers LLC bought a new stake in shares of AnaptysBio during the 2nd quarter worth $615,000. BlackRock Inc. purchased a new position in shares of AnaptysBio in the 2nd quarter worth about $124,473,000. Finally, Deutsche Bank AG purchased a new position in shares of AnaptysBio in the 2nd quarter worth about $3,165,000.

AnaptysBio Stock Performance

Shares of ANAB opened at $57.74 on Monday. The business has a 50-day moving average of $58.56 and a 200 day moving average of $58.83. AnaptysBio, Inc. has a fifty-two week low of $11.40 and a fifty-two week high of $72.36. The firm has a market cap of $1.71 billion, a P/E ratio of -53.46 and a beta of 0.72.

Analyst Upgrades and Downgrades

ANAB has been the subject of a number of research analyst reports. Leerink Partners set a $90.00 price objective on shares of AnaptysBio in a report on Friday, May 15th. HC Wainwright started coverage on shares of AnaptysBio in a research note on Wednesday, June 10th. They issued a “buy” rating and a $95.00 target price on the stock. Wall Street Zen downgraded shares of AnaptysBio from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 16th. Zacks Research lowered shares of AnaptysBio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. Finally, Barclays lifted their price target on shares of AnaptysBio from $63.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, May 13th. Nine investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, AnaptysBio presently has a consensus rating of “Moderate Buy” and a consensus target price of $82.00.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.